slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 35,521-35,550
Pages 3,683
Rows per page 30
Component
35,521-35,550 of 110,471
122
The slide uses red arrows and dots to visually demonstrate the discrepancy between cited data and the actual study graph.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
192
The slide uses a Q&A format to present expert testimony regarding trial unblinding.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
193
The slide serves as a summary of deeper investigative findings regarding clinical trial data integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
194
Focuses on trial design bias and potential data suppression.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
219
The slide uses Q&A transcripts to highlight internal knowledge of safety risks and potential for generic substitution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
255
The slide uses direct quotes to frame the company's actions as predatory and unethical.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
277
The slide uses a Q&A format to highlight negative expert sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
289
Uses Q&A format to highlight expert skepticism and safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
301
The slide uses a Q&A format to highlight specific allegations of misconduct regarding clinical trial reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
316
The slide uses Q&A transcripts to undermine the perceived market success of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
317
The slide uses direct quotes from a trial investigator to undermine the drug's clinical value and commercial prospects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
334
The slide uses direct quotes from a trial investigator to undermine the value proposition of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
337
Uses direct quotes from an investigator to undermine the credibility of clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
348
The slide presents interview transcripts highlighting a lack of buzz at a major industry conference.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
353
The slide uses a Q&A format to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
400
The slide uses a combination of summary bullet points and verbatim Q&A transcripts to highlight the expert's negative assessment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
410
The slide uses Q&A transcripts to highlight the expert's skepticism regarding Vykat's value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
19
The slide uses expert quotes and technical reasoning to discredit a competitor's product claims.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The Struggle2 hits
24
The slide uses a narrative approach to discredit Lasertec's technical strategy by highlighting past rejections of current partners.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The StruggleLoop · Cost Of Inaction2 hits
26
Includes direct quotes from industry experts regarding customer sentiment and the competitive landscape for EUV mask inspection tools.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The StruggleLoop · Cost Of Inaction2 hits
29
The slide uses anecdotal evidence from industry interviews to support a thesis of operational failure and reputational decline at Intel.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The StruggleLoop · Cost Of Inaction2 hits
45
The slide uses highly charged, competitive language ('catastrophic', 'game over', 'will disappear') to frame the competitive threat.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The Victory2 hits
53
The slide uses strong, accusatory language ('fraud', 'epic scam') to frame the findings of an investigative report.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The Victory2 hits
15
The slide uses a short-selling thesis style, highlighting valuation concerns and legal/regulatory risks in the medical air transport industry.TransMedics (TMDX) · Scorpion Capital
Research note Short seller Beat · Critique of TransMedics Group Inc.2 hits
48
The slide uses direct quotes from a formal letter to refute claims.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
51
The slide uses a 'Q&A' format to document expert interviews, highlighting the lack of choice for customers.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
52
The slide uses Q&A transcripts to highlight forced reliance on third-party technicians and procurement teams, which the experts view as a significant operational drawback.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
73
The slide uses a Q&A format to present testimony regarding unethical business practices and overbilling.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
75
The slide uses Q&A transcripts to expose a contradiction between operational efficiency and the company's new logistics model.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits
83
The slide uses a Q&A format to highlight specific instances of alleged fraud, emphasizing the lack of transparency and the financial impact of unnecessary air travel.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 2 hits